Peter Ghiloni - Mar 11, 2022 Form 4 Insider Report for cbdMD, Inc. (YCBD)

Role
Director
Signature
/s/ Peter Ghiloni
Stock symbol
YCBD
Transactions as of
Mar 11, 2022
Transactions value $
$0
Form type
4
Date filed
4/19/2022, 04:39 PM
Previous filing
Oct 5, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction YCBD Common Stock Award $0 +5K +1.64% $0.00 310K Mar 11, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction YCBD Stock Options (Right to Buy) Award +30K 30K Mar 11, 2022 Common Stock 30K $0.82 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The grant was exempt from Section 16(b) under the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder as it was approved in advance by the Issuer's Compensation, Corporate Governance and Nominating Committee, which is comprised of four non-employee directors. The restricted stock units vest quarterly in equal increments on June 30, 2022, September 30, 2022, December 31, 2022 and March 31, 2023, subject to continued service as a director of the Issuer on each applicable vesting date. Shares of common stock will be delivered to the Reporting Person upon the vesting of the restricted stock units. The restricted stock units were issued under the 2021 Equity Compensation Plan as compensation to the Reporting Person for his services on the Issuer's Board of Directors for the Board term beginning March 11, 2022.
F2 The stock options were granted under the 2021 Equity Compensation Plan as compensation to the Reporting Person for his services on the Issuer's Board of Directors for the Board term beginning March 11, 2022. The grant was exempt from Section 16(b) under the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder as it was approved in advance by the Issuer's Compensation, Corporate Governance and Nominating Committee, which is comprised of four non-employee directors. The stock options are fully vested.
F3 Not applicable.